Reid Hoffman, the co-founder of LinkedIn and a prominent figure in Silicon Valley, has announced his decision to step down from Microsoft’s Board of Directors to focus on his latest venture, Manus AI. This move marks a significant shift in Hoffman’s professional trajectory, as he transitions from his advisory role at Microsoft to a more hands-on leadership position in the burgeoning field of AI-driven drug discovery.
**A Decade of Influence at Microsoft**
Hoffman joined Microsoft’s board in 2017, following the tech giant’s acquisition of LinkedIn for $26.2 billion. During his tenure, he played a pivotal role in shaping Microsoft’s strategic direction, particularly in the realm of artificial intelligence. Notably, Hoffman was instrumental when Microsoft invested its first $1 billion into OpenAI in 2019, reflecting his deep involvement in the AI sector. His dual role as an investor and board member underscored his commitment to advancing AI technologies within Microsoft’s ecosystem.
**Transition to Manus AI**
In a recent episode of his “Possible” podcast, Hoffman discussed his decision to return to “founder mode” with Manus AI, a startup dedicated to revolutionizing drug discovery through artificial intelligence. He expressed enthusiasm about the progress Manus has made, stating, “One of the things I realized over the last month was that, we’re seeing such progress with Manus. I need to get back to founder mode.” ([techcrunch.com](https://techcrunch.com/2026/06/05/reid-hoffman-is-leaving-microsofts-board-to-go-founder-mode-with-startup-manus/?utm_source=openai))
Manus AI, co-founded by Hoffman and Dr. Siddhartha Mukherjee—a physician, biologist, and Pulitzer Prize-winning author—is an AI-native biopharmaceutical company. The startup aims to transform the clinical pipeline from target to medicine by integrating pioneering AI technology with the fundamental principles of chemistry, physics, and biology. This innovative approach seeks to expedite the drug discovery process, potentially leading to more effective treatments for various diseases.
**Implications for Microsoft’s AI Initiatives**
Hoffman’s departure from Microsoft’s board comes at a time when the company is intensifying its focus on artificial intelligence. His decision to dedicate himself fully to Manus AI may influence Microsoft’s future AI strategies, especially considering his previous involvement in significant AI investments and partnerships. However, Microsoft has not indicated any immediate changes to its AI initiatives following Hoffman’s announcement.
**Looking Ahead**
As Hoffman transitions to lead Manus AI, the tech industry will be closely watching the developments in AI-driven drug discovery. Hoffman’s extensive experience in both technology and venture capital positions him uniquely to drive innovation in this sector. His commitment to returning to a founder’s role underscores his dedication to shaping the future of healthcare through artificial intelligence.
This strategic move by Hoffman highlights the dynamic nature of the tech industry, where leaders continually seek new challenges and opportunities to make a significant impact. It also reflects the growing importance of AI in various sectors, including healthcare, and the potential for transformative advancements in drug discovery.
Hoffman’s decision to step down from Microsoft’s board to focus on Manus AI is a testament to his entrepreneurial spirit and his belief in the transformative power of artificial intelligence. As he embarks on this new venture, the industry anticipates the innovative contributions he will bring to the field of drug discovery.
This article is AI-generated content. Please verify the information independently before taking any action based on this article.
